BioSight
Companies
Zenas BioPharma, Inc. logo

ZBIO

NASDAQWALTHAM, MA
Zenas BioPharma, Inc.

Zenas BioPharma develops drug candidates for immunology and inflammation diseases using various therapeutic approaches. The company is in preclinical and clinical development stages across multiple product candidates, with efforts to establish clinical differentiation and build a balanced portfolio. Zenas is working to advance these programs toward potential regulatory approval and commercialization, including pursuing orphan drug designations for certain candidates.

Price history not yet available for ZBIO.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar